**Supplementary file**

Table 5. Evolution of means and group medians of delirium symptoms among participants of EG and CG between M1 and M2

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Symptoms CAMa | *M* | *Median* | *CI 95%* | *Ub* | *zc* | *P* |
| Measure | IL | UL |
| M1 | EG | 2.71 |  | 2.20 | 3.21 | 1190.00 |  | .395 |
|  | CG | 2.38 |  | 1.92 | 2.85 |  |  |  |
| M2 | EG | 1.90 |  | 1.46  | 2.34 | 2396.00 |  | .084 |
|  | CG | 2.50 |  | 1.97  | 3.03 |  |  |  |
| M1*vs*M2 | EG | - | 2.45 | - | - | - | 2.97 | **.003\*** |
| CG | - | 2.18 | - | - | - |  |  |
| EG | - | 1.68 | - | - | - |  |  |
| CG | - | 2.23 | - | - | - | -.28 | .781 |

Note. a delirium symptoms with CAM ;b Mann-Whitney U test ;c Wilcoxon Test ; \* p < 0,05; CI= Confidence Interval ; IL= Inferior level ; UL= Upper Level

Table 5a

*Covariance analysis (ANCOVA) of the delirium symptoms at M2 adjusted for confounding variables (n=103)*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Parameters | A | ES | *t* | *P* | CI 95% | ηf | AdjustedMeans |
| IL | UL |
| Constant | 5.26 | 2.71 | 1.94 | .056 | -.13 | 10.65 | .04 |  |
| Symptoms deliriuma | 0.12 | .13 | .91 | .363 | -.14 | .38 | .01 |  |
| Cognitive impairmentb | -.17 | .05 | -3.63 | **.000\*** | -.27 | -.08 | .12 |  |
| Poly-medication | -.01 | .06 | -.22 | .827 | -.13 | .10 | .00 |  |
| Age | .01 | .02 | .23 | .823 | -.04 | .05 | .00 |  |
| Comorbiditiesc | .05 | .05 | 1.07 | .289 | -.05 | .15 | .01 |  |
| Control Groupd | -.58 | .29 | -2.02 | **.046\*** | -1.14 | -.01 | .04 | 2.49 |
| Experimental Group | .00e |  |  |  |  |  |  | 1.91 |

*Note*. a CAM at M1 ; b MMSE at M1; c CIRS-G; d Adjustment of Bonferroni of CI ; e Parameter put on zero because redundant; f Eta square= effect size ; \* *p* < 0,05 CI= Confidence Interval ; BI= Inferior limit ; LS= Superior limit.

Table 6 Evolution of the means of the MMSE among the participants of the EG and CG at M1 and M2

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Measure | MMSEa | *M* | *SD* | CI 95% | *t* | dfb | CI 95% | *p* |
| IL | UL | IL | UL |
| M1 |  |  |  |  |  | .16c | 101 | .15 | .96 | .873 |
|  | EG | 23.96 | 4.53 | 22.69 | 25.24 |  |  |  |  |  |
|  | CG | 23.81 | 5.17 | 22.37 | 25.25 |  |  |  |  |  |
| M2 |  |  |  |  |  | 1.44c | 101 | -.47 | 2.97 | .152 |
|  | EG | 25.06 | 3.63 | 24.04 | 26.08 |  |  |  |  |  |
|  | CG | 23.81 | 5.04 | 22.40 | 25.21 |  |  |  |  |  |
| M1 |  |  |  |  |  |  |  |  |  |  |
| *Vs* | EG | -1.10 | 2.69 | - | - | -2.91d | 50 | -1.86 | -.34 | **.005\*** |
| M2 | CG | .00 | 2.13 | - | - | .00d | 51 | -.59 | .59 | 1.000 |

*Note*. a Mini-Mental State Examination ; b degrees of freedom ; c *t*-test for independent samples ; d *t*-test for paired samples ; \**p* < 0,05 CI= Confidence Interval ; IL= Inferior limit ; UL= Upper limit.

Table 6a Covariance analysis (ANCOVA) of the cognitive impairment at M2 adjusted for confounding variables (n=103)

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Parameter | A | ES | *t* | *P* | CI 95% | ηe | Adjustedmeans |
| IL | UL |
| Constant | 7.57 | 3.43 | 2.21 | .030 | .76 | 14.37 | .05 |  |
| Cognitive Impairmenta | .77 | .05 | 16.08 | **.000\*** | .68 | .87 | .73 |  |
| Poly-médication | .05 | .09 | .58 | .570 | -.13 | .23 | .00 |  |
| Age | -.01 | .03 | -.43 | .669 | -.08 | .05 | .00 |  |
| Comorbiditiesb | -.09 | .08 | -1.15 | .254 | -.25 | .07 | .01 |  |
| Control groupc | 1.08 | .44 | 2.47 | **.015\*** | .21 | 1.95 | .06 | 23.89 |
| Experimental group | .00d |  |  |  |  |  |  | 24.97 |

*Note*. a MMSE at M1; b CIRS-G; c Adjustment of Bonferroni CI ; d Parameter put on zero because redundant; e Eta square= effect size ; \**p* < 0,05 ; CI= Confidence Interval ; IL= Inferior limit ; UL= Upper limit.

Table 7. Evolution of the mean scores of ADL/AIDL among the participants of the EG and CG at M1 and M2

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Measure | ADL/IADLa | *M* | *SD* | CI 95% | *T* | dfb | CI 95% | *p* |
| IL | UL | IL | UL |
| M1 |  |  |  |  |  | .08c | 101 | -3.35 | 3.63 | .938 |
|  | EG | 32.36 | 8.20 | 29.85 | 34.46 |  |  |  |  |  |
|  | CG | 32.02 | 9.58 | 29.35 | 34.69 |  |  |  |  |  |
| M2 |  |  |  |  |  | -1.19c | 101 | -5.73 | 1.42 | .235 |
|  | GE | 29.16 | 8.53 | 26.76 | 31.56 |  |  |  |  |  |
|  | GT | 31.31 | 9.71 | 28.50 | 34.01 |  |  |  |  |  |
| M1 |  |  |  |  |  |  |  |  |  |  |
| *Vs* | GE | 3.00 | 4.35 |  |  | 4.93d | 50 | 1.78 | 4.22 | **.000\*** |
| M2 | GT | .71 | 5.42 |  |  | .95d | 51 | -.80 | 2.22 | .348 |

*Note*. a Activities of daily living ; b degrees of freedom ; c *t*-test for independent samples ; d *t*-test for paired samples ; \**p* < 0,05 ; IC= Confidence Interval ; IL= Inferior limit ; UL= Upper limit.

Table 7a

*Covariance analysis (ANCOVA) of ADL/IADL at M2 and the adjusted confounding variables (n=103)*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Parameter | A | ES | *t* | *P* | CI 95% | ηf | Adjusted means |
| IL | UL |
| Constant | 4.99 | 8.04 | .62 | .536 | -10.96 | 20.94 | .00 |  |
| ADL/IADLa | .79 | .08 | 10.56 | **.000\*** | .64 | .94 | .54 |  |
| Cognitive Impairmentb | -.07 | .13 | -.54 | .590 | -.34 | .19 | .00 |  |
| Poly-medication | .13 | .19 | .69 | .490 | -.24 | .50 | .01 |  |
| Age | -.05 | .07 | -.75 | .455 | -.18 | .08 | .01 |  |
| Comorbiditiesc | .43 | .17 | 2.55 | **.013\*** | .09 | .76 | .06 |  |
| Control Groupd | -.00 | .92 | -2.17 | **.033\*** | -3.83 | -.17 | .05 | 31.23 |
| Experimental group | .00e |  |  |  |  |  |  | 29.23 |

*Note*. a Activities of daily living at M1; b MMSE at M1; c CIRS-G; d Adjustment of Bonferroni of CI; e Parameter put on zero because redundant;;f Eta square = effect size; \* *p* < 0,05 ; CI= Confidence Interval ; IL= inferior limit ; UL= Upper limit.